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Summary. The development of an inhibitor repre-
sents one of the most challenging complications in
patients with haemophilia A. Optimal management
is immune tolerance induction (ITI), typically
through the administration of high doses of factor
VIII (FVIII) concentrate. Among 12 patients who
underwent ITI using Advate, a third-generation
recombinant FVIII product that is free of animal
and human protein additives, tolerance was achieved
in nine (75%), including seven of 10 patients (70%)
with high-titre inhibitors. ITI is ongoing in two
patients and not yet successful; immune tolerance
failed in the third patient. The median time to success
was 4.0 months for group as a whole and for
patients with high-titre inhibitors. Treatment was
well tolerated, and no adverse events were observed.
Advate was found to be equivalent to other FVIII
products with regard to both ITI success rates and
the incidence of adverse effects when used in these
immune tolerance regimens.
Keywords: Advate, haemophilia A, immune toler-
ance induction, inhibitor, third-generation recombi-
nant factor VIII
Introduction
The development of inhibitors, immune globulin G
antibodies that neutralize the function of factor VIII
(FVIII) [1] remains the most serious treatment com-
plication in patients with haemophilia A. Inhibitors
occur in approximately 30% of individuals with
severe haemophilia [2] and in 3–13% of those with
mild or moderate haemophilia [3] following exposure
to FVIII replacement therapy. The development of
inhibitors is linked to a variety of genetic factors [4–8]
and may also be influenced by certain environmental
factors [9–13]. The presence of an inhibitor makes the
treatment of bleeding episodes more difficult and
increases the risk of uncontrollable bleeding and
disability, particularly arthropathy [14–16].
Bleeding episodes in patients with low-titre inhibi-
tors are often effectively managed with high-doses of
FVIII. Bypassing agents are typically needed to
control haemorrhage in patients with high-titre
inhibitors [15], defined as a historical peak titre
exceeding 5 Bethesda units (BU mL)1) [17]). The
haemostatic efficacy of bypassing products is difficult
to predict, however, it does not reach the overall
success rates obtained with FVIII replacement in
patients without inhibitors [18–21]. Consequently,
immune tolerance induction (ITI) is often undertaken
in patients with high-responding inhibitors in an
effort to achieve antigen tolerance, and restore
normal or near-normal FVIII replacement kinetics
[22]. Historically, approximately 50% to nearly
80% of patients are successfully tolerized, according
to date from the International [23], North American
[24], and German [25] ITI registries.
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Aim
This study describes 12 children who underwent ITI
using a third-generation recombinant FVIII (rFVIII)
concentrate (Advate rAHF-PAFM; Baxter Health-
care Corp., Westlake Village, CA, USA) that is
formulated using a plasma/albumin-free method to
eliminate the risk of blood-borne pathogen
transmission [26].
Patients and methods
The records of 12 children with severe haemophilia
A, who developed inhibitors and used Advate for
immune tolerance over a period of 30 months
following the approval of Advate by the US Food
and Drug Administration in July 2003 were reviewed
for data abstraction and analysis. ITI regimens were
prescribed by the treating physician. Information for
all patients was retrospectively provided via anony-
mous data collection forms.
The pharmacokinetic parameters used to define ITI
success are those established by consensus at the
Second International Conference on Immune Toler-
ance held in Bonn, Germany in 1997. These para-
meters include an undetectable inhibitor level
(<0.6 BU mL)1), FVIII plasma recovery ‡66% of
predicted, FVIII half-life of ‡6 h after a 72-h FVIII
washout period and the absence of anamnesis upon
further FVIII exposure [27]. The definitions of good
risk and poor risk used in this study are the same
ones that are being using in the International ITI
(I-ITI) Study [28]:
• Good risk: age <8 years, inhibitor present
<12 months, peak inhibitor titre £200 BU mL)1
and inhibitor titre at the start of ITI <10 BU mL)1.
• Poor risk: age >8 years, inhibitor present
>12 months, peak inhibitor titre>200 BU mL)1
and inhibitor titre at the start of ITI >10 BU mL)1.
Results
Patient 1
Patient 1 was diagnosed with severe haemophilia A
at the age of 7 days. At the age of 23 months and
following 24 exposure days to rFVIII, including both
Recombinate (Baxter Healthcare Corp., Westlake
Village, CA, USA.) and Advate (total cumulative
dosage: 1139 IU kg)1), an inhibitor measuring
1.8 BU mL)1 was detected during routine surveil-
lance. ITI was initiated using rFVIII, including
Advate, at a dose of 100 IU kg)1 day)1. The inhibi-
tor peaked at 5.6 BU mL)1 upon initiation of ITI but
was undetectable after 3 months. Thirty-six months
after the patient was successfully tolerized, his
inhibitor titre was measured at <0.8 BU mL)1.
Patient 2
Patient 2 was diagnosed with severe haemophilia A
within hours of birth because of excessive bruising
following vaginal delivery. An inhibitor measuring
5 BU mL)1 was detected during routine surveil-
lance when the child was 10 months old and had
had a total of 10 exposure days to Recombinate
(total cumulative dose: 583 IU kg)1). ITI was
initiated immediately using Advate at a dose of
100 IU kg)1 day)1. During ITI, the peak inhibitor
titre was 19 BU mL)1. Two serious soft tissue
haemorrhages were treated with a total of three
doses of activated recombinant factor VII (rFVIIa;
Novo Nordisk, Bagsvaerd, Denmark). ITI was
deemed successful after 5 months, at which time
the inhibitor titre measured <0.8 BU mL)1. Thirty-
six months after the completion of ITI, the child’s
inhibitor titre was measured at <0.8 BU mL)1.
Patient 3
Patient 3 was diagnosed with severe haemophilia A
at the age of 5 months. An inhibitor measuring
89.6 BU mL)1 was detected 2 months later when a
soft tissue haematoma was refractory to standard
doses of rFVIII. Prior to this bleeding event, the child
had had four exposure days to Recombinate and
Advate (total cumulative dose: 143 IU kg)1). Once
the inhibitor was detected, subsequent bleeding
episodes were treated with rFVIIa at a dose of
90–120 mcg kg)1 administered every 2–3 h until
bleeding resolved (2–10 doses). After 2.5 years, the
child’s inhibitor titre had decreased to 12.4 BU mL)1
and ITI was started using rFVIII, including Advate,
at a dose of 100 IU kg)1 administered twice daily.
Despite 52 months of high-dose ITI, the inhibitor has
persisted; the patient’s most recent inhibitor titre was
23 BU mL)1. Immune tolerance is ongoing with a
plasma-derived FVIII that has a high concentration
of von Willebrand factor.
Patient 4
Patient 4 was born to a known carrier of severe
haemophilia A and was diagnosed with severe
haemophilia A at birth. His maternal uncle is also
affected with severe haemophilia A and developed a
low-titre inhibitor that was successfully eradicated
using a plasma-derived FVIII concentrate. A central
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venous access device (CVAD) was placed and
primary prophylaxis with Advate was started at the
age of 10 months. Three months later, after 46
exposure days to rFVIII (total cumulative dose:
4820 IU kg)1), an inhibitor measuring 4.2 BU mL)1
was detected. ITI was initiated with Advate at a dose
of 100 IU kg)1 day)1. Tolerance was achieved after
9 months, and the child’s most recent inhibitor titre,
measured 28 months after the completion of ITI, was
<0.6 BU mL)1.
Patient 5
Patient 5 was also born to a known carrier of
haemophilia A and was diagnosed with severe
disease at birth. His maternal uncle had a high-titre
inhibitor that was successfully eradicated using a
combination of plasma-derived and rFVIII. When
this patient was 15 months old, a CVAD was placed
to allow administration of primary prophylaxis. One
month later, after 13 exposure days to Advate (total
cumulative dose: 353 IU kg)1), he developed signif-
icant bruising, and an inhibitor measuring
32 BU mL)1 was diagnosed. Over the next
6 months, rFVIIa was used to treat bleeding epi-
sodes, and his antibody titre decreased to
2 BU mL)1. ITI was started using Advate
100 IU kg)1 daily. Immune tolerance was achieved
after 6 months of treatment; the child’s most recent
inhibitor titre, measured 22 months after the com-
pletion of ITI, was <0.6 BU mL)1.
Patient 6
Patient 6 was diagnosed with severe haemophilia A
at 1 year of age. His family history includes a third
cousin with haemophilia and an inhibitor. At the age
of 15 months and following 14 exposure days to
Advate (total cumulative dose: 1135 IU kg)1), the
patient was diagnosed with an inhibitor measuring
150 BU mL)1. ITI was initiated immediately using
Advate at a dose of 100 IU kg)1 twice daily. The
child was successfully tolerized after 4 months; his
most recent inhibitor titre, measured 19 months after
completing ITI, was <0.6 BU mL)1.
Patient 7
Patient 7 was diagnosed with severe haemophilia A
at the age of 7 months because of excessive
bruising. During the ensuing months, he had
trauma-related bleeding, particularly in the gluteal
area, but had no evidence of joint bleeding. At the
age of 19 months, following 14 exposure days to
Recombinate and Advate (total cumulative dosage:
540 IU kg)1), he was diagnosed with an inhibitor
when his mother observed that increasingly larger
doses of factor were needed to treat bleeding
episodes. His inhibitor titre at diagnosis measured
1.3 BU mL)1. A CVAD was placed under rFVIIa
coverage, and ITI was initiated with Advate at a
daily dose of 100 IU kg)1. His pre-ITI titre was
11 BU mL)1. After 3 months, his antibody titre had
decreased to <0.5 BU mL)1. Daily ITI was contin-
ued for a total of 11 months. The patient currently
receives Advate at a dose of 80 IU kg)1 three times
weekly, and his inhibitor titre has remained
<0.5 BU mL)1.
Patient 8
Patient 8 was diagnosed with severe haemophilia A
2 days after birth because of excessive bleeding
following circumcision. When the child was
22 months old and had more than 25 exposure days
to rFVIII (Helixate FS; ZLB Behring, Kankakee, IL,
USA) (total cumulative dose: 1745 IU kg)1), an
inhibitor measuring 1.4 BU mL)1 was detected on
routine surveillance. One month later, his antibody
titre was <0.5 BU mL)1, and the patient’s family
decided to change infusion products to Advate. After
23 exposure days to Advate, his inhibitor level had
increased to 2.5 BU mL)1; 2 weeks later, it measured
3.8 BU mL)1. ITI was initiated using Advate at a
dose of 100 IU kg)1 day)1 and was successful after
21 days. Daily ITI was continued for approximately
12 months, at which time the dose was reduced to
75 IU kg)1 daily for an additional 2 months. At
month 11, the dosing frequency was decreased to six
times weekly for an additional 6 months. The patient
currently receives Advate prophylaxis 70 IU kg)1
three times weekly and his inhibitor titre has
remained <0.5 BU mL)1.
Patient 9
Patient 9 has a strong family history of haemophilia
that includes a maternal uncle with an inhibitor. The
child was diagnosed with severe haemophilia A in
utero and developed an inhibitor measuring
32 BU mL)1 at 14 months of age following 12
exposure days to Advate (total cumulative dose:
927 IU kg)1). ITI was started immediately using
Advate at a dose of 100 IU kg)1 twice daily. Within
1 month, his inhibitor titre measured <0.6 BU mL)1.
Nine months later, he continued to have a negative
titre. A modified prophylactic regimen of 74 IU kg)1
every other day is ongoing.
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Patient 10
Patient 10 was diagnosed with severe haemophilia A
at birth. His family history includes an older brother
with severe haemophilia without an inhibitor. The
patient exhibited infrequent bleeding episodes
(approximately 4–6 haemorrhages annually) and
was managed with on-demand infusions. At the age
of 6 years, following 20 exposure days to Recombin-
ate (total cumulative dose: 300 IU kg)1), the patient
exhibited increased bleeding frequency and a
decreased response to FVIII and was placed on a
twice-weekly prophylactic regimen. An inhibitor
measuring 7.9 BU mL)1 was subsequently diag-
nosed. Eight months after diagnosis, the patient was
enrolled in the I-ITI and was randomized to the low-
dose regimen of 50 IU kg)1 three times weekly (the
high-dose regimen used in the I-ITI is 200 IU kg)1
daily) [28]. Advate was used for ITI. The patient was
initially non-adherent to the ITI regimen and was
withdrawn from the I-ITI. Adherence was reestab-
lished several months after ITI initiation (new dose:
Advate 100 IU kg)1 bid), but the clinical course was
complicated by major trauma, including an upper
extremity compartment syndrome that required
fasciotomy and multiple CVAD infections. ITI has
continued for a total of 27 months. The most recent
inhibitor titre was 13.8 BU mL)1.
Patient 11
Patient 11 was diagnosed with severe haemophilia A
11 days after birth when he presented with postcir-
cumcision bleeding. He was treated with fresh frozen
plasma in the newborn nursery; at the age of
15 days, he first received rFVIII (Kogenate FS; Bayer
HealthCare LLC, Tarrytown, NY, USA). At the age
of 13 months, following 11 exposure days to
Kogenate FS (total cumulative dose: 400 IU kg)1),
an inhibitor measuring 14 BU mL)1 was diagnosed
when a bleeding event failed to respond to standard
therapy. Subsequently, bleeding episodes were man-
aged with rFVIIa at standard doses. Immune toler-
ance was postponed because the child’s mother
wished to avoid the need for port placement.
A low-dose ITI regimen was initiated 4 years after
inhibitor diagnosis using Advate 115 IU kg)1 three
times weekly. After 18 months, his inhibitor titre
was measured at <0.6 BU mL)1. A pharmacokinetic
study performed after 21 months of therapy showed
a FVIII recovery of 76% and a half-life of 6–8 h. The
patient’s most recent inhibitor titre, measured
2 years after the completion of ITI, remains
<1.0 BU mL)1.
Patient 12
Patient 12 was diagnosed with severe haemophilia A
at 11 months of age because of extensive bruising.
His family history includes a maternal uncle with
haemophilia complicated by an inhibitor. At the age
of 13 months, following four exposure days to
Recombinate, an inhibitor measuring 24.4 BU mL)1
was diagnosed. ITI was started 11 months later
when his titre was 7.1 BU mL)1 using Recombinate
and Kogenate at a dose of 200 IU kg)1 once daily.
The patient was subsequently changed to Advate at
the parent’s request. During ITI, the inhibitor titre
peaked at 989.7 BU mL)1. ITI was discontinued
after 44 months, at which time the inhibitor titre
measured 18 BU mL)1.
Tables 1 and 2 and Figs 1–3 show the data for
these 12 patients.
Discussion
Among the 12 patients with severe haemophilia A
described in this report, five (patients 1, 2, 4, 7 and 8)
had inhibitor titres £5 BU mL)1 and seven (patients 3,
5, 6, 9, 10, 11 and 12) had titres >5 BU mL)1 at initial
detection of the inhibitor (Table 1). The inhibitors
developed approximately 1 year after the diagnosis of
haemophilia and after an average of 15.5 exposure
days (median, 13.0 days; range, 4–46 days) to FVIII
replacement concentrate (Figure 1). ITI, the only
treatment for eradicating inhibitors [2], was per-
formed, with Advate used at some time during each
patient’s ITI regimen (between 0–907 days after
inhibitor diagnosis). Overall, tolerance was achieved
in nine patients (75%) after a median of 4.0 months
(average, 5.5 months) (Figure 2), which corresponds
to success rates of 50–80% reported by the Interna-
tional, North American and German ITI registries
[23–25] and to historical success rates of 75–82%
observed by investigators in the United States [29] and
Sweden [30], respectively. Eight of the patients
described (1, 2, 4, 5, 7, 8, 10 and 12) fulfilled the
criteria for good risk used in the ongoing I-ITI Study
(Table 2, Figure 3) [28]. ITI was successful in six of
these patients (75%), is ongoing in one patient (10)
and failed in one patient (12). Immune tolerance was
also successful in three of four patients (6, 9, 11; 75%)
who met the I-ITI criteria for poor risk. ITI is ongoing
in patient 3.
Low-titre inhibitors
Cases 4 and 8 are representative of low-titre inhibi-
tors that remit with ITI (Table 2). It is possible that
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these patients had transient inhibitors, defined as
low-titre antibodies that gradually disappear over
time [31,32]. Transient inhibitors accounted for
20–55% of the anti-FVIII antibodies reported in
three rFVIII studies of previously untreated patients
[33–35], and their development suggests that natural
tolerance to exogenous clotting factor can occur.
However, as both patients reported here experienced
bleeding episodes, it can be argued that their inhibi-
tors were clinically significant, and that ITI was
appropriate. ITI was initiated in patient 4 because of
serious bleeding episodes coupled with family history














(months)High Low Poor Good
1 X X Successful 3
2 X X Successful 5
3 X X Ongoing 52
4 X X Successful 9
5 X X Successful 6
6 X X Successful 4
7 X X Successful 3
8 X X Successful 0.7
9 X X Successful 1
10 X X Ongoing 27
11 X X Successful 18
12 X X Failure 44









































1 7 days 23 months 24 1.8 1.8 1.8 0 days 100 qd 5.6 <0.8 3
2 1 day 10 months 10 5 19 3.6 0 days 100 qd 19 <0.8 5
3 5 months 7 months 4 89.6 1823 12.4 2.5 years 200 qd 96.5 23 (52)
4 1 day 13 months 46 4.2 4.2 4.2 0 days 100 qd 4.2 <0.6 9
5 1 day 16 months 13 24 38.4 2 6 months 100 qd 2 <0.6 6
6 12 months 15 months 13 150 150 150 0 days 200 qd 150 <0.6 4
7 7 months 19 months 14 1.3 11 1.3 3 months 100 qd 11 <0.5 3
8 2 days 22 months 15 2.5 3.8 2.5 1 month 100 qd 3.8 <0.5 0.7
9 1 day 14 months 12 32 37 32 0 days 200 qd 37 <0.6 1
10 1 day 6 years 20 7.9 49.8 4.6 8 months 100 tiw 49.8 13.8 (27)
11 12 days 13 months 11 14 43 0 4 years 100 tiw 8.8 <1.0 18
12 11 months 13 months 4 24.4 989.7 7.1 11 months 200 qd 989.7 19 (44)*
Median 14.5 months 13.0 10.95 37.7 3.9 4.0
Low 1.3 1.8
High 150 1823
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Fig. 1. Time and exposure days to inhibitor development.
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of an inhibitor. In patient 8, ITI was started when the
inhibitor persisted for 1 month. ITI at a daily dose of
100 IU kg)1 was successful in both patients with
low-titre inhibitors.
High-titre inhibitors
Cases 1, 2, 5, 6, 7, 9 and 11 are examples of high-titre,
high-responding inhibitors that were successfully
eliminated with ITI (Table 2). High-titre inhibitors
are characterized by brisk anamnesis (peak historical
titre >5 BU mL)1 [17]) and the resultant inability to
treat bleeding episodes with specific factor replace-
ment [15]. Historically, high-responding antibodies
were thought to account for approximately 80% of all
inhibitors [36]. However, data from studies of previ-
ously untreated patients exposed to rFVIII indicate
that the true incidence of high-titre inhibitors ranges
from 41% to 53% [33–35]. Four of our patients (1, 2,
6 and 9) started ITI immediately upon detection of the
high-titre inhibitor, and two (6 and 9) were treated
with a high-dose regimen (Advate 200 IU kg)1 day)1)
(Table 1). Three patients (5, 7 and 11) did not begin
ITI until 6 months, 3 months and 4 years, respec-
tively, after inhibitor detection. During the interval
between inhibitor diagnosis and the start of ITI,
bleeding events in patient 5 and 7 were managed with
rFVIIa to avoid the theoretical possibility of an
anamnestic response to trace amounts of FVIII present
in activated prothrombin complex concentrate (FEI-
BA; Baxter, Deerfield, IL, USA). Patient 11 was treated
with both rFVIIa and FEIBA to control bleeding.
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Fig. 2. Response of patients to ITI therapy.





































Fig. 3. Response to ITI based on prognostic
factors. Interval inhibitor titres were avail-
able for eight patients prior to and during ITI
therapy. Black symbols represent patients
with favourable prognostic features, as
defined by the I-ITI study; symbols in red
denote patients with unfavourable prognostic
factors.
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Despite intensive ITI for 52, 27 and 44 months,
respectively, patients 3, 10 and 12 represent high-
titre, high-responding inhibitors that persist despite
ITI (Table 2). These children developed inhibitors
after 4, 20 and 4 exposure days, respectively
(Table 1). Because patients 3 and 12 had inhibitor
titres that exceeded 10 BU mL)1 at diagnosis
(89.6 BU mL)1 and 24.4 BU mL)1, respectively),
ITI was delayed for 2.5 years and 11 months,
respectively. Patients 3 and 12 received an aggressive
ITI regimen of Advate 200 IU kg)1 daily, and patient
10 received Advate 100 IU kg)1 three times weekly.
Ultimately, 20–50% of patients undergoing ITI fail
to become tolerized [23,24,27]. One possibility is
that the immune systems of these patients are
dysfunctional and the inhibitors are entrenched. ITI
failure may also be attributable, at least in part, to
uncertainties about the optimal dosing regimen and
the ideal time to initiate ITI. The I-ITI Study,
launched in 2002, is evaluating the efficacy, morbid-
ity and cost-effectiveness of low- vs. high-dose ITI in
inhibitor patients with a good prognosis (i.e. age
<8 years, inhibitor present <12 months, maximum
inhibitor titre £200 BU mL)1, inhibitor titre
<10 BU mL)1 at the start of ITI), but the results will
not be known for several years [37].
It is noteworthy that immune tolerance can be
beneficial even when the inhibitor is not eradicated.
When ITI reduces the titre to £5 BU mL)1, FVIII can
be used to control bleeding in an emergency situation
until anamnesis occurs, typically after 6–7 days [21].
The choice of factor concentrate for use in ITI is
controversial and is being investigated as part of the
I-ITI study. Recently, Kurth et al. described the
impact of a FVIII concentrate containing von Wille-
brand factor (FVIII/VWF) on ITI outcome in 25
patients considered to have a poor prognosis for
successful tolerization because of clinical and labo-
ratory characteristics or because of a poor response
to initial ITI with a monoclonal antibody-purified or
recombinant FVIII concentrate [38]. Among 11
patients who started ITI with a FVIII/VWF concen-
trate, all attained partial tolerance after an average of
15 months (range: 1–62 months), and three patients
achieved complete tolerance after an average of
38 months of ITI. Among 14 patients who initially
started ITI with a monoclonal or recombinant FVIII
product and subsequently switched to a FVIII/VWF
concentrate, five attained complete tolerance within
3–14 months following the product change. While
these data are tantalizing, it remains unclear whether
the type of FVIII concentrate contributes to ITI
success. Nonetheless, patients who fail to respond to
ITI with monoclonal or recombinant concentrates
may benefit from a change to products containing
VWF.
Safety
ITI with Advate was associated with anamnesis
during ITI in three patients (1, 2, and 7). This
phenomenon is expected during immune tolerance
with any FVIII-containing product and, therefore,
does not represent a safety issue specific to Advate.
No other adverse events, including viral transmis-
sion, occurred.
Conclusion
Advate is a third-generation rFVIII product that
can be used to effectively and safely induce
immune tolerance in patients with severe haemo-
philia A and inhibitors, including those with high
titre inhibitors. The overall success rate of 75% at
a median of 4.0 months observed in our patients
corresponds to that reported to the ITI registries,
and the 70% success rate among the 10 patients
with high-titre inhibitors is similar to that reported
to the ITI registries and observed by other inves-
tigators.
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